De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis

Table 1 Baseline characteristics of patients with HBV-related decompensated cirrhosis n (%)

Variables	LAM + ADV (n = 45)	ETV (n = 45)	t	χ2	P value
Age (yr)	53.1 ± 8.8	53.2 ± 7.4	0.23		> 0.05
Male/female	29/16	28/17		3.10	> 0.05
HBV DNA (log10 copy/mL)	6.56 ± 1.13	6.61 ± 1.15	0.33		> 0.05
ALT (U/L)	98.1 ± 21.6	99.8 ± 17.2	0.23		> 0.05
TBil (μmol/L)	51.6 ± 8.9	49.2 ± 6.8	0.31		> 0.05
Alb (g/L)	29.2 ± 0.7	29.5 ± 1.2	0.24		> 0.05
PT (s)	16.3 ± 2.3	16.5 ± 1.9	0.21		> 0.05
CTP score	8.4 ± 1.7	8.6 ± 2.1	0.16		> 0.05
MELD score	13.7 ± 3.5	12.9 ± 6.7	0.25		> 0.05
HBeAg positive rate	23 (51.1)	22 (48.9)		2.13	> 0.05
Ascites	22 (48.9)	21 (46.7)		2.46	> 0.05
HE	6 (13.3)	7 (15.5)		3.13	> 0.05
UGB	9 (22.2)	8 (17.8)		3.35	> 0.05

ALT: Alanine aminotransferase; TBil: Total bilirubin; Alb: Albumin; PT: Prothrombin time: CTP: Child-Turcotte-Pugh; MELD: Model for end-stage liver disease; HE: Hepatic encephalopathy; UGB: Upper gastrointestinal bleeding; HBeAg: Hepatitis B e antigen.